多囊卵巢综合征合并代谢综合征临床特点及治疗进展

被引：65

作者：

张春梅

赵越

乔杰

机构：

[1] 北京大学第三医院妇产科生殖医学中心教育部辅助生殖重点实验室北京市生殖内分泌与辅助生殖重点实验室

来源：

中国实用妇科与产科杂志 | 2016年 / 32卷 / 09期

关键词：

多囊卵巢综合征; 代谢综合征; 药物治疗;

D O I：

暂无

中图分类号：

R711.75 [卵巢疾病]; R589 [代谢病];

学科分类号：

100201 [内科学]; 100211 [妇产科学];

摘要：

<正>多囊卵巢综合征（PCOS）是育龄期女性最常见的生殖内分泌紊乱性疾病,在世界范围内发病率高达5%10%[1]。PCOS的病因复杂,是遗传和环境因素共同作用的结果,临床表现高度异质性,诊断标准尚不统一。目前应用较为广泛的是2003年美国生殖医学会鹿特丹会议提出的诊断标准[2]。PCOS是一种生殖功能障碍与多种内分泌代谢异常共存的疾病。在生殖功能方面,PCOS患者出现无排卵性不孕、流产和妊娠期合并症等风险显著增加;在全身健康方面,PCOS患者远期发生

引用

页码：915 / 918

页数：4

共 13 条

[1]

Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study [J].

Jensterle, Mojca ;

Goricar, Katja ;

Janez, Andrej .

EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2016, 11 (04) :1194-1200

[2]

Lipoprotein Particles in Adolescents and Young Women With PCOS Provide Insights Into Their Cardiovascular Risk [J].

Gourgari, E. ;

Lodish, M. ;

Shamburek, R. ;

Keil, M. ;

Wesley, R. ;

Walter, M. ;

Sampson, M. ;

Bernstein, S. ;

Khurana, D. ;

Lyssikatos, C. ;

Ten, S. ;

Dobs, A. ;

Remaley, A. T. ;

Stratakis, C. A. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (11) :4291-4298

[3]

Targets to treatmetabolic syndrome in polycystic ovary syndrome [J].

Mahalingaiah, Shruthi ;

Diamanti-Kandarakis, Evanthia .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2015, 19 (11) :1561-1574

[4]

Reflections on inositol(s) for PCOS therapy: steps toward success [J].

Nestler, John E. ;

Unfer, Vittorio .

GYNECOLOGICAL ENDOCRINOLOGY, 2015, 31 (07) :501-505

[5]

Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease [J].

Kahal, H. ;

Abouda, G. ;

Rigby, A. S. ;

Coady, A. M. ;

Kilpatrick, E. S. ;

Atkin, S. L. .

CLINICAL ENDOCRINOLOGY, 2014, 81 (04) :523-528

[6]

Effects of Acarbose on Polycystic Ovary Syndrome: A Meta-analysis [J].

Zhang, Y. -Y. ;

Hou, L. -Q. ;

Zhao, T. -Y. .

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2014, 122 (06) :373-378

[7]

Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates.[J].Pratap Kumar;Shweta Arora.Journal of Human Reproductive Sciences.2014, 4

[8]

The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome [J].

Panidis, Dimitrios ;

Tziomalos, Konstantinos ;

Papadakis, Efstathios ;

Chatzis, Panagiotis ;

Kandaraki, Eleni A. ;

Tsourdi, Elena A. ;

Katsikis, Ilias .

CLINICAL ENDOCRINOLOGY, 2014, 80 (03) :432-438

[9]

Hypertension in women with polycystic ovary syndrome: prevalence and associated cardiovascular risk factors.[J].Yuhua Shi;Yuqian Cui;Xuedong Sun;Gang Ma;Zengxiang Ma;Qin Gao;Zi-jiang Chen.European Journal of Obstetrics and Gynecology.2014,

[10]

Effects of Exercise on Insulin Resistance and Body Composition in Overweight and Obese Women with and without Polycystic Ovary Syndrome [J].

Hutchison, Samantha K. ;

Stepto, Nigel K. ;

Harrison, Cheryce L. ;

Moran, Lisa J. ;

Strauss, Boyd J. ;

Teede, Helena J. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (01) :E48-E56

← 1 2 →